Skip to main content
LLM 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Session III: AML and MDS

Debate: All Non-FLT3 Mutated AML Patients Above Age 60 with ELN Intermediate or Adverse Risk Should Be Treated with Azacitidine and Venetoclax - YES

Wednesday, October 18, 2023
2:45 PM – 3:00 PM ET
Location: Metropolitan East

    Debate Speaker(s)

  • Pinkal Desai, MD

    Weill Cornell Medicine
    New York, New York, United States